Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Acetone
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(11)
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Heavy menstrual bleeding: assessment and management (NG88)
Linzagolix for treating symptoms of endometriosis (TA1067)
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)
Neonatal parenteral nutrition (NG154)
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Trials: 8 · 1967–2025
Showing the 50 most relevant studies, sorted by most relevant.
Geng Zhang, Hideshi Hattori, Kozo Tanabe
Applied Catalysis, 1988
Y.-T. Seo, S.-P. Kang, H. Lee
Fluid Phase Equilibria, 2001
Mohamd Laimon, Sattar Jabbar Murad Algayyim, S. Rahman, et al.
Multidisciplinary Digital Publishing Institute, 2022
A.L. Andreassen, S.H. Bauer
Journal of Molecular Structure, 1972
A.P. Hitchcock, C.E. Brion
Journal of Electron Spectroscopy and Related Phenomena, 1980
A. Wisthaler, N.R. Jensen, R. Winterhalter, et al.
Atmospheric Environment, 2001
V. M. Akhil, Samarth J. Mangalore, M. C. Chinmay, et al.
Virtual and Physical Prototyping, 2024
Manju K. Mathew, N. Madhavan Unny, Arun George, et al.
Journal of Veterinary and Animal Sciences, 2024
Sujeet , Rai, Samraj, Mollick, Bartolomeo , Civalleri, et al.
2023
Despite exhaled human breath having enabled noninvasive diabetes diagnosis, selective acetone vapor detection by fluorescence approach in the diabetic range (1.8-3.5 ppm) remains a long-standing challenge. We report a set of water-resistant luminescent metal-organic framework (MOF)-based composites for detecting acetone vapor in the diabetic range with a limit of detection of 200 ppb. The luminescent materials can also detect acetone vapor selectively unimpeded by excessive water vapor and other competing VOCs mixture, and it can be reused in minutes under ambient conditions. Industrially pertinent electrospun unique luminescent fibers were likewise fabricated alongside various luminescent films for selective detection of ultratrace quantities of acetone vapor present in the air. Ab initio theoretical calculations combined with in situ synchrotron-based dosing studies uncovered the material’s remarkable hypersensitivity towards acetone vapor. Finally, a freshly designed prototype fluorescence-based portable optical sensor was utilized for the rapid detection of acetone vapor within the diabetic range
Abstract licence: CC BY-NC-ND
Marija, Stojkovic
2024
Over the last fifteen years, immense progress has been made in the research of pressure-swing batch distillation. The challenge lies in the fact that certain pressure-sensitive azeotropic mixtures cannot be separated in a regular open batch mode, with an acceptable outcome. Throughout most of this text, findings are to contradict previously grounded facts. Acetone-methanol separation by pressure-swing batch distillation in a mixed double system consisting of a regular and inverted double column is a process under investigation. In this work, a complete global solution to the optimal control problem in form of a sequential synthesis of controlled trajectories is derived. During this study, the optimal reflux strategy through cyclic operation was extended to the separation of a non-ideal minimum boiling azeotrope of industrial significance. The influence of the liquid ratio and tank volume on the control pattern and energy requirement is evaluated as well
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.